Taurine
Evidence Fact Sheet
Taurine is a conditionally essential sulfonic amino acid that supports osmoregulation, antioxidant defense, mitochondrial tRNA function and cardiac calcium handling. Human meta-analyses report modest improvements in blood-pressure and metabolic-syndrome markers; EFSA rejected all taurine health claims. FDA GRAS; research doses 1.5-6 g/day.
Also known as: Taurine · 2-aminoethanesulfonic acid · L-taurine
Overview
Taurine (2-aminoethanesulfonic acid) is a conditionally essential sulfur-containing amino acid found in high concentration in heart, muscle, brain and retina, and a natural component of breast milk and infant formula. Mechanistically it acts in cell-volume osmoregulation, antioxidant free-radical scavenging (taurine chloramine), conditionally essential mitochondrial tRNA wobble modification, and calcium handling / membrane stabilization in cardiomyocytes, with reported activity at the TauT transporter (SLC6A6) and GABA-A / glycine receptors. Human research uses oral doses roughly in the 1.5-6 g/day range (lower for acute pre-exercise use, energy drinks around 1000 mg/serving), with a large safety margin. Regulatory status: FDA GRAS (GRN 586) and an Old Dietary Ingredient under DSHEA (structure/function claims only); a legal EU food ingredient, though EFSA rejected all taurine health claims in 2011 and noted no safety concern at routine intake; an ANVISA-permitted supplement and energy-drink constituent; and an authorized nutritional fortifier in China. It is not a stimulant and must not be marketed as lasting energy or a caffeine substitute.
Mechanism of Action
Osmoregulation / cell-volume control · Antioxidant / free-radical scavenging (taurine chloramine) · Mitochondrial tRNA modification (conditionally essential for mt-tRNA wobble modification) · Calcium handling / membrane stabilization in cardiomyocytes
Body systems: Cardiovascular · METABOLISM · Musculoskeletal · Mitochondrial & Cellular Energy
Evidence-Based Benefits
Each benefit below is anchored to a specific PubMed-indexed study. Effect sizes, sample sizes, and p-values are reported as published; no values are inferred. Honest negatives and null results are kept alongside the positive findings, and disease-research populations are described as such — Taurine is not characterized as a treatment for any disease.
Cardiovascular / Blood Pressure
Meta-analysis supported- -3.999 mm Hgsystolic BP · p=0.017
- -1.435 mm Hgdiastolic BP
- 20 RCTs / 808trials · participants
A 2024 systematic review and meta-analysis pooling 808 participants across 20 randomized controlled trials found that oral taurine produced modest but statistically significant reductions in systolic and diastolic blood pressure and heart rate, plus a higher left-ventricular ejection fraction. These are surrogate cardiovascular markers in studied populations, not hard cardiac-event outcomes.
Reported effect: Systolic BP WMD = -3.999 mm Hg (95% CI -7.293 to -0.706, p = 0.017); diastolic BP WMD = -1.435 mm Hg (95% CI -2.484 to -0.386, p = 0.007); heart rate WMD = -3.579 bpm (p = 0.004); LVEF WMD = 4.981% (p = 0.004); 808 participants from 20 RCTs
“Pooled analysis of 808 participants from 20 randomized controlled trials. Systolic: WMD = -3.999 mm Hg, 95% CI = -7.293 to -0.706, p = 0.017. Diastolic: WMD: -1.435 mm Hg, 95% CI: -2.484 to -0.386, p = 0.007. Heart rate: WMD = -3.579 bpm, 95% CI = -6.044 to -1.114, p = 0.004. Left ventricular ejection fraction: WMD: 4.981%, 95% CI: 1.556 to 8.407, p = 0.004.”
Source: PMID 39148075 · Tzang 2024 · Nutrition Journal
Metabolic Syndrome Markers
Meta-analysis supported- -5.882 mg/dLfasting glucose · p=0.018
- -18.315 mg/dLtriglycerides · p<0.001
- 25 RCTs / 1024trials · participants
A 2024 meta-analysis of 25 RCTs (1024 participants, taurine 0.5-6 g/day) reported significant reductions in fasting blood glucose, triglycerides and blood pressure versus control across metabolic-syndrome-related markers. Effects were on surrogate markers, not on metabolic-syndrome diagnosis or hard outcomes.
Reported effect: Fasting blood glucose WMD = -5.882 mg/dL (95% CI -10.747 to -1.018, p = 0.018); triglycerides WMD = -18.315 mg/dL (95% CI -25.628 to -11.002, p < 0.001); systolic BP WMD = -3.999 mmHg (p = 0.017); 1024 participants from 25 RCTs
“Our analysis included 1024 participants from 25 RCTs. The daily dosage of taurine in the studies ranged from 0.5 g/day to 6 g/day... taurine supplementation demonstrated statistically significant reductions in SBP (WMD = -3.999 mmHg, 95% CI = -7.293 to -0.706, p = 0.017), DBP (WMD = -1.509 mmHg, 95% CI = -2.479 to -0.539, p = 0.002), FBG (WMD: -5.882 mg/dL, 95% CI: -10.747 to -1.018, p = 0.018), TG (WMD: -18.315 mg/dL, 95% CI: -25.628 to -11.002, p < 0.001)”
Source: PMID 38755142 · Tzang 2024 · Nutrition & Diabetes
HDL Cholesterol (Null Finding)
Null / no benefit Meta-analysis supported- 0.644 mg/dlHDL-C · p=0.155 (NS)
Honest negative: in the same 2024 metabolic-syndrome meta-analysis (25 RCTs, 1024 participants), taurine did NOT significantly change HDL cholesterol. This shows the benefit signal does not extend to every lipid fraction.
Reported effect: HDL-C WMD = 0.644 mg/dl (95% CI -0.244 to 1.532, p = 0.155) — not statistically significant
“but not in HDL-C (WMD: 0.644 mg/dl, 95% CI: -0.244 to 1.532, p = 0.155).”
Source: PMID 38755142 · Tzang 2024 · Nutrition & Diabetes
Glycemic Control & Lipids in Overweight/Obesity
Meta-analysis supported- -2.15 µU/mLfasting insulin · p=0.0001
- -0.33%HbA1c (obese) · p=0.002
- 9 RCTsincluded trials
A 2024 systematic review and meta-analysis of 9 RCTs of long-term taurine in adults with overweight or obesity found significant reductions in fasting insulin, total cholesterol and triglycerides overall, with HbA1c and HOMA-IR improving specifically in obese participants. The authors note glycemic benefits were most pronounced at doses around 3 g/day.
Reported effect: Fasting insulin WMD = -2.15 µU/mL (95% CI -3.24 to -1.06, p = 0.0001); HbA1c WMD = -0.33% (95% CI -0.53 to -0.12, p = 0.002, obese only); HOMA-IR WMD = -0.91 (p = 0.003, obese only); 9 RCTs
“The final number of studies that met the inclusion criteria was 9 RCTs. The overall analysis showed that taurine supplementation significantly decreased TG (WMD = -0.56 mg/dL, 95% CI: -0.92 to -0.2, p = 0.002), TC (WMD = -0.71 mg/dL, 95% CI: -1.17 to -0.25, p = 0.002), and fasting insulin (WMD = -2.15 µU/mL, 95% CI: -3.24 to -1.06, p = 0.0001). ... improvements in HbA1c (WMD = -0.33%, 95% CI: -0.53 to -0.12, p = 0.002) and HOMA-IR (WMD = -0.91, 95% CI: -1.74 to -0.08, p = 0.003) were observed only in obese participants”
Source: PMID 39796489 · Sun 2024 · Nutrients
Endurance Exercise Performance
Meta-analysis supported- g = 0.40endurance · p=0.004
- g = 0.43time-to-exhaustion · p=0.007
A 2018 meta-analysis (10 peer-reviewed articles) found a small-to-moderate, statistically significant improvement in endurance exercise performance with oral taurine, similar in time-to-exhaustion trials. Notably, the dose (1-6 g/day) did not moderate the effect, and acute versus chronic supplementation did not differ.
Reported effect: Endurance performance Hedges' g = 0.40 (95% CI 0.12-0.67, P = 0.004); time-to-exhaustion subanalysis Hedges' g = 0.43 (95% CI 0.12-0.75, P = 0.007); dose did not moderate effect (P > 0.05)
“Taurine ingestion improved overall endurance performance (Hedges' g = 0.40, 95% CI 0.12-0.67, P = 0.004) ... which was similar in TTE trials (Hedges' g = 0.43, 95% CI 0.12-0.75, P = 0.007). The dose of taurine did not moderate its effect on endurance performance (P > 0.05).”
Source: PMID 29546641 · Waldron 2018 · Sports Medicine
Portal Hypertension (Cirrhosis)
RCT supported- -12%HVPG change · p=0.0093
- 22 patientsefficacy analysis
- 7 of 12taurine responders >10%
In a randomized placebo-controlled study of oral taurine 6 g/day in cirrhosis (22 patients in the efficacy analysis), the hepatic venous pressure gradient fell significantly in the taurine arm while placebo did not change. This is a single small trial on a surrogate hemodynamic endpoint, not an outcome study.
Reported effect: Taurine HVPG fell from 20 mm Hg (±4) to 18 mm Hg (±4) at day 28, mean relative change -12% (P = 0.0093); placebo +2% (P = 0.4945); 7/12 (58%) taurine patients achieved HVPG response >10% vs none on placebo (P = 0.0053); n = 22 in efficacy analysis
“Thirty patients were screened and 22 included in the efficacy analysis (12 taurine/10 placebo... mean HVPG dropped from 20 mm Hg (±4) at baseline to 18 mm Hg (±4) on day 28 (mean relative change: -12%, P = .0093)... Seven of 12 patients (58%) on taurine achieved a HVPG response >10%, compared to none in the placebo group (P = .0053).”
Source: PMID 29105115 · Schwarzer 2018 · Aliment Pharmacol Ther
Vascular Endothelial Function (Mixed / Partial Null)
Null / no benefit RCT supported- n = 15 / 14taurine / placebo
- 6 g · 2 wkdose · duration
Honest mixed result: in 29 healthy men, 6 g/day taurine for 2 weeks significantly increased resting flow-mediated dilation, but it did NOT prevent the reduction in FMD seen 96 hours after a bout of resistance exercise. The resting-vasodilation benefit is qualitative in the abstract (direction only, no extractable effect-size number).
Effect size: this study reports the direction of the finding but does not state a specific numeric effect size, so none is given here rather than estimated.
“Twenty-nine healthy men...randomly assigned to either the placebo supplement group (n = 14) or the taurine supplement group (n = 15)... consumed 6 g of either a placebo or the taurine supplement for 2 weeks... Two weeks of taurine supplementation significantly increased both relative and absolute FMDs [at rest]... taurine supplementation did not improve resistance exercise-induced reduction in FMD.”
Source: PMID 31468418 · Ra 2019 · Adv Exp Med Biol
Antioxidant Status / Healthy Aging
RCT supportedIn a double-blind RCT of 24 women aged 55-70, 1.5 g/day taurine for 16 weeks raised plasma taurine and superoxide dismutase (SOD) and prevented the decline in this antioxidant enzyme seen in the control group. The abstract reports direction only and gives no usable effect-size number or p-value, so no figure is extracted.
Effect size: this study reports the direction of the finding but does not state a specific numeric effect size, so none is given here rather than estimated.
“Taurine and superoxide dismutase (SOD, antioxidant enzyme) plasma levels were increased in the GTAU group. SOD levels also were higher than in the GC group after supplementation... Taurine supplementation prevented the decrease in the antioxidant enzyme SOD, suggesting taurine as a strategy to control oxidative stress during the aging process.”
Source: PMID 35700594 · Abud 2022 · Nutrition
Cognitive Function (Taurine Alone — Null)
Null / no benefit Meta-analysis supported- g = -0.30blood lactate · CrI crosses 0
Honest negative for the popular energy-drink pairing: a 2025 systematic review and network meta-analysis of caffeine and taurine found that taurine alone did not show a clear independent effect — its estimate for a physiological marker (blood lactate) was non-significant with a credible interval crossing zero, and benefits were attributed to caffeine + taurine co-supplementation rather than taurine monotherapy on cognition or physical capacity.
Reported effect: Taurine alone: blood lactate g = -0.30 (95% CrI -1.01 to 0.42) — credible interval crosses zero (non-significant); no isolated significant cognitive/physical effect reported for taurine monotherapy
“TAU showed a possible tendency toward reducing B[la] ... g = -0.30, 95% CrI [-1.01, 0.42] ... CAF+TAU co-supplementation provides a balanced ergogenic effect.”
Source: PMID 41032459 · Deng 2025 · J Int Soc Sports Nutr
Dosage (research context · not a recommendation)
1.5-3 g/day for most directions (CV/endothelial 1.5-3 g/day x 8-12 wk; metabolic syndrome 1.5-6 g/day, >=3 g/day better; serum lipids 3 g/day x 7 wk); acute endurance 1-6 g single dose pre-exercise. Energy drinks ~1000 mg/serving. Large safety margin (EFSA: single 6 g no adverse effects).
Regulatory Status · 4 Markets
- US · FDA
- GRAS (GRN 586, non-carbonated flavored water-based beverages) + Old Dietary Ingredient under DSHEA (pre-1994, no NDI required); structure/function claims only; no authorized health claim
- EU · EFSA
- Legal food ingredient (not Novel Food); energy-drink use legal. EFSA 2009 safety opinion: no safety concern at routine exposure. ALL taurine health claims REJECTED by EFSA 2011 (heart/fatigue/cognition/vision)
- CN · China
- China: GB 14880-2012 authorized nutritional fortifier plus nutrient-supplement pathway and registered anti-fatigue compound health-foods.
- BR · ANVISA
- Permitted food-supplement & energy-drink constituent (RDC 243/2018 / RDC 273/2005 limit 400 mg/100 mL); no taurine-specific functional claim authorized
Safety
Well tolerated at 3-6 g/day long-term across multiple RCTs/meta-analyses; high doses occasionally mild GI discomfort. EFSA 2009: no safety concern at routine intake. FDA GRAS (GRN 586). Theoretical additive effect with antihypertensive/antidiabetic drugs; may lower serum lithium (caution in psychiatric patients). Natural component of breast milk/infant formula. Not a stimulant — must not be marketed as lasting energy or a caffeine substitute.
Related
Goals: heart-health
Lifestyles: athletic-performance
References
PubMed-indexed citations anchoring the benefit findings above. Effect sizes are reported as published.
- PMID 39148075 · Tzang 2024 · Nutrition Journal — Cardiovascular / Blood Pressure
- PMID 38755142 · Tzang 2024 · Nutrition & Diabetes — Metabolic Syndrome Markers
- PMID 39796489 · Sun 2024 · Nutrients — Glycemic Control & Lipids in Overweight/Obesity
- PMID 29546641 · Waldron 2018 · Sports Medicine — Endurance Exercise Performance
- PMID 29105115 · Schwarzer 2018 · Aliment Pharmacol Ther — Portal Hypertension (Cirrhosis)
- PMID 31468418 · Ra 2019 · Adv Exp Med Biol — Vascular Endothelial Function (Mixed / Partial Null)
- PMID 35700594 · Abud 2022 · Nutrition — Antioxidant Status / Healthy Aging
- PMID 41032459 · Deng 2025 · J Int Soc Sports Nutr — Cognitive Function (Taurine Alone — Null)
Frequently Asked Questions
1. What does the human evidence actually show for taurine?
The strongest evidence is pooled meta-analyses on surrogate markers. A 2024 meta-analysis (20 RCTs, 808 participants) reported modest blood-pressure reductions (systolic -3.999 mm Hg, diastolic -1.435 mm Hg), and a separate 2024 meta-analysis (25 RCTs, 1024 participants) found lower fasting glucose (-5.882 mg/dL) and triglycerides (-18.315 mg/dL). These are research findings on markers in studied populations, not evidence that taurine treats any disease.
2. Does taurine improve athletic or endurance performance?
A 2018 meta-analysis of 10 articles found a small-to-moderate, statistically significant improvement in endurance performance (Hedges' g = 0.40) and in time-to-exhaustion trials (g = 0.43). Interestingly, the effect was not moderated by dose across the 1-6 g/day range studied, and acute versus chronic dosing did not differ.
3. What are the honest negative findings?
Several. The 2024 metabolic-syndrome meta-analysis found NO significant change in HDL cholesterol (p = 0.155). An RCT in healthy men found 6 g/day raised resting flow-mediated dilation but did not prevent the post-resistance-exercise FMD decline. And a 2025 network meta-analysis found taurine alone had no clear independent effect (its blood-lactate estimate crossed zero), with benefits attributed to caffeine + taurine together rather than taurine on its own.
4. What doses are used in research, and is taurine safe?
Human studies typically use roughly 1.5-6 g/day (lower single doses for acute pre-exercise use; energy drinks around 1000 mg/serving). The card notes taurine is well tolerated at 3-6 g/day long-term across multiple RCTs, with occasional mild GI discomfort at high doses, and EFSA found no safety concern at routine intake. This is evidence reporting, not dosing advice — discuss any supplement use with a qualified professional.
5. Is taurine approved to make health claims?
No. In the US it is GRAS (GRN 586) and an Old Dietary Ingredient under DSHEA, allowing only structure/function claims with no authorized health claim. EFSA rejected ALL taurine health claims in 2011 (heart, fatigue, cognition, vision) while treating it as a legal food ingredient. ANVISA permits it as a supplement/energy-drink constituent without a taurine-specific functional claim, and China authorizes it as a nutritional fortifier.
6. Is taurine a stimulant or an energy booster?
No. Taurine is a conditionally essential amino acid, not a stimulant, and the card explicitly notes it must not be marketed as lasting energy or a caffeine substitute. In the caffeine-and-taurine network meta-analysis, the ergogenic signal was tied to caffeine + taurine combinations, not to taurine acting as an independent energy source.
Last evidence review: 2026-06-13